$131 Million is the total value of Devon Park Associates, LLC's 4 reported holdings in Q4 2014. The portfolio turnover from Q3 2014 to Q4 2014 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ZSPH | New | ZS Pharma Inc | $107,114,000 | – | 2,576,723 | +100.0% | 81.67% | – |
| CARA | New | Cara Therapeutics Inc | $11,484,000 | – | 1,151,894 | +100.0% | 8.76% | – |
| CEMP | New | Cempra Inc | $9,172,000 | – | 390,144 | +100.0% | 6.99% | – |
| PRTO | New | Proteon Therapeutics Inc | $3,388,000 | – | 325,727 | +100.0% | 2.58% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-02-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Inotek Pharmaceuticals Corporation | 7 | Q3 2016 | 100.0% |
| ZS Pharma Inc. | 4 | Q3 2015 | 89.5% |
| Cara Therapeutics Inc. | 2 | Q1 2015 | 8.8% |
| Proteon Therapeutics Inc. | 2 | Q1 2015 | 2.8% |
| Cempra Inc | 1 | Q4 2014 | 7.0% |
View Devon Park Associates, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2017-01-06 |
| 13F-HR | 2016-11-14 |
| 13F-HR | 2016-08-15 |
| 13F-HR | 2016-05-03 |
| 13F-HR | 2016-02-09 |
| 4 | 2015-12-21 |
| 13F-HR | 2015-11-16 |
| 13F-HR | 2015-08-14 |
| 4 | 2015-07-16 |
| 13F-HR | 2015-05-13 |
View Devon Park Associates, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.